Rayson, D., Richel, D., Chia, S., Jackisch, C., Van der Vegt, S., & Suter, T. (2008). Anthracycline–
trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and
future strategies. Annals of Oncology,19(9), 1530-1539.
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer Jr, C. E., Davidson, N. E., ... & Wolmark,
N. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast
cancer. New England Journal of Medicine, 353(16), 1673-1684.
Shmeeda, H., Tzemach, D., Mak, L., & Gabizon, A. (2009). Her2-targeted pegylated liposomal
doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
Journal of Controlled Release, 136(2), 155-160.
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., ... & Norton, L.
(2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast
cancer that overexpresses HER2. New England Journal of Medicine, 344(11), 783-792.
Stickeler, E., Klar, M., Watermann, D., Geibel, A., Földi, M., Hasenburg, A., & Gitsch, G. (2009).
Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu
positive metastatic breast cancer: a multicenter phase II trial. Breast cancer research and
treatment, 117(3), 591-598.
Surveillance, Epidemiology, and End Results ProgramTurning Cancer Data Into Discovery. (n.d.).
Retrieved October 15, 2015.
Tacar, O., Sriamornsak, P., & Dass, C. R. (2013). Doxorubicin: an update on anticancer molecular
action, toxicity and novel drug delivery systems. Journal of Pharmacy and Pharmacology,
65(2), 157-170.
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., ... &
Gwyther, S. G. (2000). New guidelines to evaluate the response to treatment in solid tumors.
Journal of the National Cancer Institute,92(3), 205-216.
Trevor, A., & Katzung, B. (2013). Cancer Chemotherapy. In Katzung & Trevor's pharmacology:
Examination & board review (10th ed., p. 471). New York: McGraw-Hill Medical.
Valabrega, G., Montemurro, F., & Aglietta, M. (2007). Trastuzumab: mechanism of action, resistance
and future perspectives in HER2-overexpressing breast cancer. Annals of oncology.
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., ... & Press,
M. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of
HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology, 20(3), 719-726.